AbbVIe's Zumilokibart Meets Phase 2 Goal In Atopic Dermatitis Study
WASHINGTON (dpa-AFX) - AbbVie (ABBV) reported positive results from the Phase 2 APEX Part B study of zumilokibart, in adults with moderate to severe atopic dermatitis.All three dose regimens met the study's primary endpoint, demonstrating significantly greater EASI-75 response rates compared with p…